These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 17004104)

  • 21. Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models.
    Fujimoto-Ouchi K; Sekiguchi F; Yasuno H; Moriya Y; Mori K; Tanaka Y
    Cancer Chemother Pharmacol; 2007 May; 59(6):795-805. PubMed ID: 17031648
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
    Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G
    Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synergistic inhibition of breast cancer cell lines with a dual inhibitor of EGFR-HER-2/neu and a Bcl-2 inhibitor.
    Witters LM; Witkoski A; Planas-Silva MD; Berger M; Viallet J; Lipton A
    Oncol Rep; 2007 Feb; 17(2):465-9. PubMed ID: 17203189
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of unique synergistic drug combinations associated with downexpression of survivin in a preclinical breast cancer model system.
    Budman DR; Calabro A; Rosen L; Lesser M
    Anticancer Drugs; 2012 Mar; 23(3):272-9. PubMed ID: 23427335
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies.
    Esteva FJ; Cheli CD; Fritsche H; Fornier M; Slamon D; Thiel RP; Luftner D; Ghani F
    Breast Cancer Res; 2005; 7(4):R436-43. PubMed ID: 15987448
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Growth effect of neutrophil elastase on breast cancer: favorable action of sivelestat and application to anti-HER2 therapy.
    Nawa M; Osada S; Morimitsu K; Nonaka K; Futamura M; Kawaguchi Y; Yoshida K
    Anticancer Res; 2012 Jan; 32(1):13-9. PubMed ID: 22213283
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Combination treatment with trastuzumab and Paclitaxel as primary therapy for advanced breast cancer].
    Suzuki M; Kimijima I; Ishii M
    Gan To Kagaku Ryoho; 2009 Sep; 36(9):1519-23. PubMed ID: 19755824
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Trastuzumab and chemotherapeutics: drug interactions and synergies.
    Pegram MD; Lopez A; Konecny G; Slamon DJ
    Semin Oncol; 2000 Dec; 27(6 Suppl 11):21-5; discussion 92-100. PubMed ID: 11236023
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differential impact of Cetuximab, Pertuzumab and Trastuzumab on BT474 and SK-BR-3 breast cancer cell proliferation.
    Brockhoff G; Heckel B; Schmidt-Bruecken E; Plander M; Hofstaedter F; Vollmann A; Diermeier S
    Cell Prolif; 2007 Aug; 40(4):488-507. PubMed ID: 17635517
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ongoing and planned trials of hormonal therapy and trastuzumab.
    Nicholson BP
    Semin Oncol; 2000 Dec; 27(6 Suppl 11):33-7; discussion 92-100. PubMed ID: 11236026
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Toxicity of trastuzumab labeled 177Lu on MCF7 and SKBr3 cell lines.
    Rasaneh S; Rajabi H; Hossein Babaei M; Johari Daha F
    Appl Radiat Isot; 2010 Oct; 68(10):1964-6. PubMed ID: 20537546
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combination of standard cytotoxic agents with polyamine analogues in the treatment of breast cancer cell lines.
    Hahm HA; Dunn VR; Butash KA; Deveraux WL; Woster PM; Casero RA; Davidson NE
    Clin Cancer Res; 2001 Feb; 7(2):391-9. PubMed ID: 11234895
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination treatment with Grb7 peptide and Doxorubicin or Trastuzumab (Herceptin) results in cooperative cell growth inhibition in breast cancer cells.
    Pero SC; Shukla GS; Cookson MM; Flemer S; Krag DN
    Br J Cancer; 2007 May; 96(10):1520-5. PubMed ID: 17426702
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mitochondria-targeted nitroxides exacerbate fluvastatin-mediated cytostatic and cytotoxic effects in breast cancer cells.
    Cheng G; Lopez M; Zielonka J; Hauser AD; Joseph J; McAllister D; Rowe JJ; Sugg SL; Williams CL; Kalyanaraman B
    Cancer Biol Ther; 2011 Oct; 12(8):707-17. PubMed ID: 21799303
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of Administered Cardioprotective Drugs on Treatment Response of Breast Cancer Cells.
    Smith TA; Phyu SM; Akabuogu EU
    Anticancer Res; 2016 Jan; 36(1):87-93. PubMed ID: 26722031
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Changes in [18F]Fluoro-2-deoxy-D-glucose incorporation induced by doxorubicin and anti-HER antibodies by breast cancer cells modulated by co-treatment with metformin and its effects on intracellular signalling.
    Cooper AC; Fleming IN; Phyu SM; Smith TA
    J Cancer Res Clin Oncol; 2015 Sep; 141(9):1523-32. PubMed ID: 25579456
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identifying molecular features that distinguish fluvastatin-sensitive breast tumor cells.
    Goard CA; Chan-Seng-Yue M; Mullen PJ; Quiroga AD; Wasylishen AR; Clendening JW; Sendorek DH; Haider S; Lehner R; Boutros PC; Penn LZ
    Breast Cancer Res Treat; 2014 Jan; 143(2):301-12. PubMed ID: 24337703
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rapamycin-loaded Immunoliposomes Functionalized with Trastuzumab: A Strategy to Enhance Cytotoxicity to HER2-positive Breast Cancer Cells.
    Eloy JO; Petrilli R; Brueggemeier RW; Marchetti JM; Lee RJ
    Anticancer Agents Med Chem; 2017; 17(1):48-56. PubMed ID: 27225450
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evidence for new targets and synergistic effect of metronomic celecoxib/fluvastatin combination in pilocytic astrocytoma.
    Mercurio S; Padovani L; Colin C; Carré M; Tchoghandjian A; Scavarda D; Lambert S; Baeza-Kallee N; Fernandez C; Chappé C; André N; Figarella-Branger D
    Acta Neuropathol Commun; 2013 May; 1():17. PubMed ID: 24252689
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enhanced anti-tumor effect of trastuzumab in combination with cisplatin.
    Naruse I; Fukumoto H; Saijo N; Nishio K
    Jpn J Cancer Res; 2002 May; 93(5):574-81. PubMed ID: 12036454
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.